Taking hypoglycemic peptides as models, Eudragit L-100 and HPMC as the carriers, the solid dispersions of hypoglycemic peptides were prepared by Solvent method, and their stability and in vitro release were studied. In this paper, the cumulative release rate and DPP-IV inhibition rate of the glycemic peptide solid dispersion at 2 h were evaluated, and the solid dispersion was characterized by scanning electron microscopy, Fourier infrared spectroscopy and transmission electron microscope by optimizing the ratio of enteric-coated carrier and release regulator, and the stability of the solid dispersion under different storage times and storage temperatures was investigated. The results showed that the optimal proportion of glycemic peptide solid dispersions was hypoglycemic peptides: Eudragit L-100: HPMC=1:2:0.2, and the cumulative release of the solid dispersions prepared under this ratio for 2 h could reach 93.54%, and the DPP-IV inhibition rate still had a high level. Scanning electron microscopy and transmission electron microscopy images show that the active peptide is dispersed in a solid dispersion, and infrared spectroscopy indicates that the conformation of the secondary structure of the active peptide has changed. After making a solid dispersion, the stability of hypoglycemic peptides was significantly enhanced, and the cumulative release rate after 10 days of storage at room temperature was still as high as 90.32%, which also showed strong stability in high temperature environment. In summary, the use of solid dispersion technology can significantly improve the stability and cumulative dissolution rate on the basis of maintaining the physiological activity of hypoglycemic peptides, and this method has great reference value for the comprehensive utilization of active peptides, especially the research and development of functional foods based on active peptides.